| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 57 | 2025 | 752 | 8.350 |
Why?
|
| Antineoplastic Agents | 62 | 2024 | 2061 | 4.940 |
Why?
|
| Pancreatic Neoplasms | 36 | 2025 | 882 | 4.400 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 47 | 2025 | 1565 | 3.790 |
Why?
|
| Neoplasms | 43 | 2022 | 2470 | 2.920 |
Why?
|
| Adenocarcinoma | 18 | 2025 | 898 | 2.690 |
Why?
|
| Protein Kinase Inhibitors | 21 | 2020 | 891 | 2.480 |
Why?
|
| Amyloid Precursor Protein Secretases | 7 | 2021 | 80 | 2.170 |
Why?
|
| Liver Neoplasms | 11 | 2025 | 640 | 2.130 |
Why?
|
| Camptothecin | 18 | 2022 | 109 | 2.030 |
Why?
|
| Xenograft Model Antitumor Assays | 34 | 2024 | 814 | 2.030 |
Why?
|
| Immunoconjugates | 12 | 2021 | 103 | 1.880 |
Why?
|
| Deoxycytidine | 16 | 2025 | 165 | 1.870 |
Why?
|
| Antibodies, Monoclonal, Humanized | 27 | 2024 | 759 | 1.790 |
Why?
|
| Antibodies, Monoclonal | 21 | 2024 | 1367 | 1.610 |
Why?
|
| Quinazolines | 11 | 2015 | 244 | 1.500 |
Why?
|
| Colonic Neoplasms | 10 | 2024 | 243 | 1.490 |
Why?
|
| Drug Resistance, Neoplasm | 15 | 2024 | 759 | 1.480 |
Why?
|
| Tetrahydronaphthalenes | 3 | 2017 | 30 | 1.440 |
Why?
|
| Valine | 3 | 2017 | 81 | 1.410 |
Why?
|
| ErbB Receptors | 14 | 2016 | 607 | 1.380 |
Why?
|
| Carcinoma, Pancreatic Ductal | 9 | 2024 | 270 | 1.370 |
Why?
|
| src-Family Kinases | 4 | 2017 | 96 | 1.360 |
Why?
|
| Molecular Targeted Therapy | 11 | 2024 | 390 | 1.290 |
Why?
|
| ras Proteins | 10 | 2017 | 144 | 1.270 |
Why?
|
| Maximum Tolerated Dose | 22 | 2022 | 193 | 1.210 |
Why?
|
| Benzodioxoles | 5 | 2012 | 105 | 1.200 |
Why?
|
| Rectal Neoplasms | 8 | 2024 | 136 | 1.180 |
Why?
|
| Enzyme Inhibitors | 9 | 2020 | 827 | 1.140 |
Why?
|
| Fluorouracil | 13 | 2025 | 199 | 1.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 11 | 2018 | 359 | 1.080 |
Why?
|
| Humans | 193 | 2025 | 129621 | 1.070 |
Why?
|
| Mutation | 15 | 2021 | 3717 | 1.070 |
Why?
|
| Bevacizumab | 8 | 2024 | 129 | 1.060 |
Why?
|
| Biomarkers, Tumor | 13 | 2024 | 1181 | 0.980 |
Why?
|
| Wnt Signaling Pathway | 8 | 2024 | 170 | 0.960 |
Why?
|
| Pyridines | 7 | 2022 | 478 | 0.950 |
Why?
|
| Proto-Oncogene Proteins | 13 | 2018 | 638 | 0.920 |
Why?
|
| Cell Line, Tumor | 31 | 2024 | 3215 | 0.900 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2023 | 90 | 0.900 |
Why?
|
| Aged | 74 | 2025 | 22099 | 0.890 |
Why?
|
| Receptor, Notch1 | 3 | 2015 | 61 | 0.880 |
Why?
|
| Cetuximab | 10 | 2017 | 94 | 0.880 |
Why?
|
| Aldehyde Dehydrogenase | 6 | 2017 | 101 | 0.870 |
Why?
|
| Signal Transduction | 22 | 2019 | 4925 | 0.840 |
Why?
|
| Drugs, Investigational | 2 | 2015 | 32 | 0.830 |
Why?
|
| Immunotherapy | 5 | 2022 | 592 | 0.830 |
Why?
|
| Middle Aged | 80 | 2025 | 31150 | 0.820 |
Why?
|
| Aniline Compounds | 4 | 2011 | 98 | 0.820 |
Why?
|
| Mice, Nude | 24 | 2024 | 683 | 0.820 |
Why?
|
| Nitriles | 3 | 2011 | 172 | 0.740 |
Why?
|
| Benzimidazoles | 6 | 2024 | 162 | 0.740 |
Why?
|
| Quinolines | 3 | 2011 | 156 | 0.720 |
Why?
|
| Female | 104 | 2025 | 68770 | 0.720 |
Why?
|
| Treatment Outcome | 40 | 2024 | 10226 | 0.710 |
Why?
|
| Dose-Response Relationship, Drug | 23 | 2017 | 2012 | 0.700 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2018 | 72 | 0.700 |
Why?
|
| Anilides | 2 | 2018 | 73 | 0.690 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2022 | 530 | 0.690 |
Why?
|
| Drug Design | 6 | 2022 | 156 | 0.680 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2020 | 181 | 0.670 |
Why?
|
| Carcinoma | 3 | 2011 | 217 | 0.670 |
Why?
|
| Administration, Oral | 14 | 2017 | 786 | 0.660 |
Why?
|
| Sulfones | 4 | 2015 | 108 | 0.660 |
Why?
|
| Neoplasm Staging | 17 | 2024 | 1295 | 0.650 |
Why?
|
| Dasatinib | 2 | 2017 | 54 | 0.650 |
Why?
|
| Gene Dosage | 3 | 2015 | 143 | 0.650 |
Why?
|
| Glycine | 4 | 2015 | 165 | 0.650 |
Why?
|
| Embolization, Therapeutic | 1 | 2021 | 207 | 0.630 |
Why?
|
| Neoadjuvant Therapy | 10 | 2025 | 383 | 0.630 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 1501 | 0.630 |
Why?
|
| Medical Oncology | 8 | 2024 | 272 | 0.620 |
Why?
|
| Pyrimidinones | 4 | 2015 | 103 | 0.610 |
Why?
|
| Paclitaxel | 7 | 2025 | 217 | 0.610 |
Why?
|
| Receptors, Notch | 3 | 2015 | 84 | 0.610 |
Why?
|
| Mice | 42 | 2024 | 16937 | 0.610 |
Why?
|
| Aged, 80 and over | 30 | 2024 | 7084 | 0.610 |
Why?
|
| MAP Kinase Kinase 1 | 3 | 2015 | 76 | 0.600 |
Why?
|
| Neoplasm Metastasis | 14 | 2024 | 610 | 0.600 |
Why?
|
| Animals | 56 | 2024 | 35360 | 0.600 |
Why?
|
| Pyrimidines | 7 | 2022 | 459 | 0.580 |
Why?
|
| Adult | 64 | 2025 | 35572 | 0.580 |
Why?
|
| Pyridones | 4 | 2015 | 159 | 0.580 |
Why?
|
| Oncogene Proteins v-abl | 1 | 2017 | 5 | 0.580 |
Why?
|
| Male | 79 | 2025 | 63674 | 0.570 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2017 | 17 | 0.560 |
Why?
|
| Liver Transplantation | 1 | 2025 | 831 | 0.550 |
Why?
|
| Benzazepines | 2 | 2014 | 40 | 0.540 |
Why?
|
| Disease Models, Animal | 10 | 2024 | 4063 | 0.540 |
Why?
|
| DNA Helicases | 3 | 2024 | 149 | 0.530 |
Why?
|
| MAP Kinase Kinase Kinases | 4 | 2015 | 71 | 0.520 |
Why?
|
| Angiogenesis Inhibitors | 8 | 2018 | 220 | 0.500 |
Why?
|
| Autophagy | 1 | 2018 | 268 | 0.500 |
Why?
|
| MAP Kinase Kinase 2 | 2 | 2012 | 29 | 0.500 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2023 | 626 | 0.500 |
Why?
|
| Immunoglobulin Fc Fragments | 3 | 2021 | 39 | 0.490 |
Why?
|
| Antigens, Neoplasm | 8 | 2018 | 309 | 0.490 |
Why?
|
| Disease-Free Survival | 11 | 2023 | 648 | 0.490 |
Why?
|
| Drug Administration Schedule | 14 | 2017 | 769 | 0.480 |
Why?
|
| Patient Rights | 1 | 2015 | 11 | 0.480 |
Why?
|
| Cell Proliferation | 18 | 2024 | 2391 | 0.470 |
Why?
|
| Apoptosis | 14 | 2022 | 2503 | 0.470 |
Why?
|
| Therapies, Investigational | 1 | 2015 | 17 | 0.470 |
Why?
|
| Drug and Narcotic Control | 1 | 2015 | 28 | 0.470 |
Why?
|
| Combined Modality Therapy | 8 | 2024 | 1206 | 0.470 |
Why?
|
| Tumor Microenvironment | 6 | 2022 | 634 | 0.470 |
Why?
|
| 3' Untranslated Regions | 2 | 2012 | 138 | 0.460 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 170 | 0.450 |
Why?
|
| DNA-Binding Proteins | 5 | 2024 | 1443 | 0.440 |
Why?
|
| Azepines | 3 | 2020 | 89 | 0.430 |
Why?
|
| Prognosis | 10 | 2023 | 3794 | 0.420 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2014 | 312 | 0.410 |
Why?
|
| Epithelial-Mesenchymal Transition | 5 | 2021 | 202 | 0.400 |
Why?
|
| Methylurea Compounds | 3 | 2006 | 7 | 0.400 |
Why?
|
| Neutropenia | 7 | 2022 | 136 | 0.390 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 10 | 2019 | 259 | 0.380 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 5 | 2019 | 81 | 0.380 |
Why?
|
| Albumins | 3 | 2025 | 103 | 0.380 |
Why?
|
| Terminal Care | 1 | 2015 | 237 | 0.370 |
Why?
|
| Triple Negative Breast Neoplasms | 3 | 2019 | 197 | 0.370 |
Why?
|
| Cell Adhesion Molecules | 5 | 2018 | 173 | 0.360 |
Why?
|
| Phenylurea Compounds | 6 | 2014 | 89 | 0.360 |
Why?
|
| Survival Rate | 9 | 2025 | 1877 | 0.350 |
Why?
|
| Anus Neoplasms | 2 | 2023 | 30 | 0.350 |
Why?
|
| Gamma Rays | 2 | 2021 | 54 | 0.350 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2025 | 381 | 0.340 |
Why?
|
| Area Under Curve | 9 | 2018 | 304 | 0.340 |
Why?
|
| Leucovorin | 7 | 2025 | 69 | 0.340 |
Why?
|
| Thymidylate Synthase | 1 | 2010 | 12 | 0.340 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2018 | 396 | 0.340 |
Why?
|
| Genes, ras | 2 | 2018 | 97 | 0.340 |
Why?
|
| Drug Synergism | 2 | 2024 | 371 | 0.330 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2010 | 159 | 0.320 |
Why?
|
| Immunoblotting | 6 | 2015 | 305 | 0.310 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2010 | 177 | 0.310 |
Why?
|
| Cell Cycle Proteins | 5 | 2018 | 586 | 0.300 |
Why?
|
| Immunohistochemistry | 9 | 2019 | 1698 | 0.290 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 902 | 0.290 |
Why?
|
| Metabolic Clearance Rate | 6 | 2012 | 118 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 964 | 0.280 |
Why?
|
| Sirolimus | 4 | 2012 | 266 | 0.280 |
Why?
|
| Organoplatinum Compounds | 6 | 2014 | 41 | 0.280 |
Why?
|
| Topoisomerase II Inhibitors | 2 | 2019 | 24 | 0.280 |
Why?
|
| Pyrazoles | 4 | 2022 | 405 | 0.280 |
Why?
|
| Clinical Trials as Topic | 8 | 2024 | 1004 | 0.280 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 232 | 0.280 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2020 | 207 | 0.270 |
Why?
|
| SOXB1 Transcription Factors | 2 | 2018 | 57 | 0.270 |
Why?
|
| Membrane Proteins | 6 | 2021 | 1119 | 0.270 |
Why?
|
| Chemoembolization, Therapeutic | 3 | 2013 | 48 | 0.270 |
Why?
|
| Genetic Testing | 1 | 2009 | 428 | 0.270 |
Why?
|
| Neovascularization, Pathologic | 3 | 2018 | 297 | 0.260 |
Why?
|
| Capecitabine | 4 | 2015 | 46 | 0.260 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2020 | 643 | 0.260 |
Why?
|
| Proto-Oncogene Proteins B-raf | 6 | 2022 | 212 | 0.250 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 2344 | 0.250 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2015 | 84 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2020 | 1356 | 0.250 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2016 | 272 | 0.250 |
Why?
|
| Head and Neck Neoplasms | 3 | 2016 | 544 | 0.250 |
Why?
|
| Pancreatectomy | 2 | 2025 | 241 | 0.240 |
Why?
|
| Heterografts | 3 | 2021 | 131 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2018 | 431 | 0.240 |
Why?
|
| Microsatellite Instability | 4 | 2021 | 37 | 0.240 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2017 | 1052 | 0.240 |
Why?
|
| Survival Analysis | 7 | 2017 | 1274 | 0.240 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 4896 | 0.240 |
Why?
|
| Neoplasm Proteins | 4 | 2020 | 424 | 0.230 |
Why?
|
| Sulfonamides | 4 | 2022 | 496 | 0.230 |
Why?
|
| Cyclosporine | 2 | 2018 | 263 | 0.230 |
Why?
|
| Drug Discovery | 3 | 2016 | 131 | 0.230 |
Why?
|
| Neoplastic Stem Cells | 3 | 2018 | 380 | 0.230 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 312 | 0.230 |
Why?
|
| Societies, Medical | 2 | 2018 | 751 | 0.220 |
Why?
|
| cdc25 Phosphatases | 1 | 2024 | 15 | 0.220 |
Why?
|
| Positron-Emission Tomography | 3 | 2018 | 288 | 0.220 |
Why?
|
| Erlotinib Hydrochloride | 5 | 2015 | 70 | 0.220 |
Why?
|
| Oncologists | 1 | 2024 | 35 | 0.220 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2015 | 769 | 0.220 |
Why?
|
| Colon | 1 | 2005 | 254 | 0.210 |
Why?
|
| STAT3 Transcription Factor | 3 | 2022 | 195 | 0.210 |
Why?
|
| DNA Mismatch Repair | 3 | 2021 | 47 | 0.210 |
Why?
|
| Subacute Care | 1 | 2024 | 77 | 0.210 |
Why?
|
| TCF Transcription Factors | 2 | 2020 | 16 | 0.210 |
Why?
|
| Metastasectomy | 1 | 2023 | 19 | 0.210 |
Why?
|
| Cancer Care Facilities | 2 | 2016 | 32 | 0.200 |
Why?
|
| Time Factors | 9 | 2017 | 6556 | 0.200 |
Why?
|
| DNA | 1 | 2009 | 1400 | 0.200 |
Why?
|
| DNA Mutational Analysis | 5 | 2012 | 387 | 0.200 |
Why?
|
| Pyrazines | 2 | 2018 | 86 | 0.200 |
Why?
|
| Skilled Nursing Facilities | 1 | 2024 | 131 | 0.200 |
Why?
|
| HCT116 Cells | 4 | 2018 | 78 | 0.200 |
Why?
|
| Ephrin-B2 | 2 | 2021 | 50 | 0.200 |
Why?
|
| Biopsy | 5 | 2023 | 1097 | 0.200 |
Why?
|
| DNA Topoisomerases, Type II | 3 | 2019 | 43 | 0.200 |
Why?
|
| Cell Cycle | 4 | 2018 | 592 | 0.200 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2006 | 744 | 0.190 |
Why?
|
| Forecasting | 1 | 2023 | 359 | 0.190 |
Why?
|
| Colic | 1 | 2001 | 7 | 0.190 |
Why?
|
| Receptor, ErbB-2 | 1 | 2024 | 326 | 0.190 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2023 | 42 | 0.190 |
Why?
|
| Tumor Burden | 5 | 2018 | 286 | 0.190 |
Why?
|
| Gene Regulatory Networks | 1 | 2024 | 284 | 0.190 |
Why?
|
| Yttrium Radioisotopes | 1 | 2021 | 52 | 0.190 |
Why?
|
| Disease Management | 3 | 2024 | 589 | 0.190 |
Why?
|
| Infusions, Intravenous | 4 | 2017 | 399 | 0.180 |
Why?
|
| Trastuzumab | 1 | 2021 | 101 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 5 | 2021 | 940 | 0.180 |
Why?
|
| ADAM10 Protein | 1 | 2021 | 30 | 0.180 |
Why?
|
| Abdomen | 1 | 2001 | 118 | 0.180 |
Why?
|
| Tissue Distribution | 2 | 2012 | 315 | 0.180 |
Why?
|
| Gene Expression Profiling | 5 | 2024 | 1706 | 0.180 |
Why?
|
| Cell Plasticity | 1 | 2021 | 27 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 106 | 0.180 |
Why?
|
| Lymphoma | 1 | 2022 | 196 | 0.170 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2019 | 209 | 0.170 |
Why?
|
| Gene Knockdown Techniques | 3 | 2020 | 315 | 0.170 |
Why?
|
| Receptors, Enterotoxin | 2 | 2017 | 4 | 0.170 |
Why?
|
| Momordica charantia | 1 | 2020 | 15 | 0.170 |
Why?
|
| Diagnostic Errors | 1 | 2001 | 162 | 0.170 |
Why?
|
| Aurora Kinase A | 2 | 2020 | 55 | 0.170 |
Why?
|
| Benzoxazoles | 1 | 2020 | 20 | 0.170 |
Why?
|
| Topoisomerase I Inhibitors | 3 | 2017 | 16 | 0.170 |
Why?
|
| Neoplasm Transplantation | 6 | 2018 | 257 | 0.170 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2020 | 113 | 0.170 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2012 | 315 | 0.170 |
Why?
|
| Retrospective Studies | 10 | 2025 | 14519 | 0.170 |
Why?
|
| Half-Life | 3 | 2017 | 162 | 0.170 |
Why?
|
| Imidazoles | 2 | 2018 | 234 | 0.170 |
Why?
|
| Peptide Fragments | 1 | 2024 | 692 | 0.170 |
Why?
|
| Radiation Injuries | 1 | 2021 | 135 | 0.160 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 64 | 0.160 |
Why?
|
| Immune System | 1 | 2021 | 175 | 0.160 |
Why?
|
| Pancreas | 2 | 2022 | 306 | 0.160 |
Why?
|
| United States | 10 | 2024 | 13900 | 0.160 |
Why?
|
| Physician-Patient Relations | 1 | 2024 | 537 | 0.160 |
Why?
|
| Intestinal Neoplasms | 1 | 2019 | 28 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2020 | 91 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 4 | 2020 | 485 | 0.160 |
Why?
|
| Benzamides | 3 | 2014 | 207 | 0.160 |
Why?
|
| Benchmarking | 1 | 2020 | 176 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2018 | 328 | 0.160 |
Why?
|
| Phosphatidylinositol 3-Kinase | 2 | 2016 | 26 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2017 | 187 | 0.160 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2020 | 60 | 0.160 |
Why?
|
| Receptor, EphB4 | 1 | 2019 | 36 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2010 | 2535 | 0.150 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2020 | 63 | 0.150 |
Why?
|
| Oligopeptides | 2 | 2018 | 257 | 0.150 |
Why?
|
| Melanoma | 2 | 2018 | 730 | 0.150 |
Why?
|
| Patient Compliance | 2 | 2021 | 565 | 0.150 |
Why?
|
| CDC2 Protein Kinase | 1 | 2018 | 31 | 0.150 |
Why?
|
| Plant Extracts | 1 | 2020 | 199 | 0.150 |
Why?
|
| Intestine, Small | 1 | 2019 | 150 | 0.150 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 98 | 0.150 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2009 | 123 | 0.150 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 285 | 0.150 |
Why?
|
| Aminobenzoates | 1 | 2018 | 7 | 0.150 |
Why?
|
| Communication | 1 | 2024 | 846 | 0.150 |
Why?
|
| Fibrosis | 1 | 2021 | 520 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2019 | 511 | 0.150 |
Why?
|
| TWEAK Receptor | 1 | 2017 | 5 | 0.140 |
Why?
|
| Chemoradiotherapy | 4 | 2023 | 210 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2024 | 857 | 0.140 |
Why?
|
| Cytochrome P-450 CYP3A | 3 | 2008 | 87 | 0.140 |
Why?
|
| Kidney Diseases | 1 | 2001 | 384 | 0.140 |
Why?
|
| Radiosurgery | 1 | 2020 | 321 | 0.140 |
Why?
|
| Faculty, Medical | 1 | 2020 | 264 | 0.140 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 55 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2020 | 857 | 0.140 |
Why?
|
| beta Catenin | 2 | 2016 | 223 | 0.140 |
Why?
|
| Cytochrome P-450 Enzyme System | 3 | 2008 | 151 | 0.140 |
Why?
|
| Breast Neoplasms, Male | 1 | 2017 | 29 | 0.140 |
Why?
|
| Taxoids | 2 | 2008 | 98 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2015 | 375 | 0.130 |
Why?
|
| Niacinamide | 3 | 2012 | 75 | 0.130 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 39 | 0.130 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 102 | 0.130 |
Why?
|
| Specimen Handling | 1 | 2017 | 164 | 0.130 |
Why?
|
| Guanylate Cyclase | 1 | 2016 | 35 | 0.130 |
Why?
|
| Tankyrases | 1 | 2016 | 14 | 0.130 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2016 | 22 | 0.130 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2017 | 89 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2018 | 307 | 0.130 |
Why?
|
| Disease Progression | 7 | 2022 | 2635 | 0.130 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 99 | 0.130 |
Why?
|
| Gonanes | 2 | 2013 | 27 | 0.130 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2015 | 25 | 0.130 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 3 | 2022 | 45 | 0.130 |
Why?
|
| Myenteric Plexus | 1 | 1995 | 4 | 0.120 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2015 | 27 | 0.120 |
Why?
|
| Jagged-1 Protein | 1 | 2015 | 23 | 0.120 |
Why?
|
| Young Adult | 8 | 2024 | 12426 | 0.120 |
Why?
|
| Phthalazines | 1 | 2016 | 41 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 198 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 5 | 2017 | 253 | 0.120 |
Why?
|
| RNA, Small Interfering | 2 | 2015 | 587 | 0.120 |
Why?
|
| Cohort Studies | 7 | 2024 | 5420 | 0.120 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2006 | 179 | 0.120 |
Why?
|
| Gene Duplication | 1 | 2015 | 67 | 0.120 |
Why?
|
| Device Approval | 1 | 2015 | 21 | 0.120 |
Why?
|
| Receptor, ErbB-3 | 1 | 2015 | 45 | 0.120 |
Why?
|
| Retinaldehyde | 1 | 2015 | 5 | 0.120 |
Why?
|
| RNA Interference | 3 | 2016 | 448 | 0.120 |
Why?
|
| Acetaldehyde | 1 | 2015 | 17 | 0.120 |
Why?
|
| Fatigue | 4 | 2012 | 318 | 0.120 |
Why?
|
| RNA, Messenger | 4 | 2020 | 2708 | 0.120 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2015 | 161 | 0.120 |
Why?
|
| Acridines | 1 | 2014 | 7 | 0.120 |
Why?
|
| Nitric Oxide Synthase | 1 | 1995 | 237 | 0.110 |
Why?
|
| Immunoglobulin G | 2 | 2017 | 847 | 0.110 |
Why?
|
| Gene Expression Regulation | 1 | 2024 | 2548 | 0.110 |
Why?
|
| Drug Approval | 1 | 2015 | 88 | 0.110 |
Why?
|
| Protein Isoforms | 1 | 2016 | 391 | 0.110 |
Why?
|
| Muscle, Smooth | 1 | 1995 | 157 | 0.110 |
Why?
|
| Neuropilin-1 | 1 | 2014 | 9 | 0.110 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2020 | 195 | 0.110 |
Why?
|
| Piperidines | 1 | 2015 | 198 | 0.110 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 210 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 74 | 0.110 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 204 | 0.110 |
Why?
|
| Chromatography, Liquid | 2 | 2006 | 423 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2017 | 387 | 0.110 |
Why?
|
| Protein Binding | 2 | 2018 | 2121 | 0.110 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 43 | 0.110 |
Why?
|
| Sensitivity and Specificity | 5 | 2009 | 1838 | 0.110 |
Why?
|
| Cell Growth Processes | 1 | 2013 | 52 | 0.110 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2022 | 375 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 455 | 0.110 |
Why?
|
| Hedgehog Proteins | 1 | 2014 | 188 | 0.110 |
Why?
|
| Piperazines | 1 | 2016 | 342 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 295 | 0.100 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2006 | 524 | 0.100 |
Why?
|
| Patient Selection | 3 | 2018 | 663 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2012 | 9 | 0.100 |
Why?
|
| Uveal Neoplasms | 1 | 2012 | 10 | 0.100 |
Why?
|
| Random Allocation | 1 | 2013 | 346 | 0.100 |
Why?
|
| Cholangiocarcinoma | 1 | 2013 | 77 | 0.100 |
Why?
|
| Demography | 2 | 2010 | 279 | 0.100 |
Why?
|
| Aldehyde Dehydrogenase, Mitochondrial | 3 | 2017 | 23 | 0.100 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 79 | 0.100 |
Why?
|
| Receptors, CXCR4 | 1 | 2012 | 83 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2022 | 7131 | 0.100 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 157 | 0.100 |
Why?
|
| Flow Cytometry | 2 | 2019 | 1156 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 3408 | 0.090 |
Why?
|
| Organoids | 2 | 2024 | 104 | 0.090 |
Why?
|
| Polyneuropathies | 1 | 2011 | 51 | 0.090 |
Why?
|
| Transplantation, Heterologous | 4 | 2016 | 192 | 0.090 |
Why?
|
| Exanthema | 2 | 2018 | 74 | 0.090 |
Why?
|
| Hepatectomy | 2 | 2016 | 212 | 0.090 |
Why?
|
| CA-19-9 Antigen | 1 | 2010 | 22 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2012 | 216 | 0.090 |
Why?
|
| Thiazoles | 1 | 2011 | 117 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2013 | 1205 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2001 | 1902 | 0.090 |
Why?
|
| Reproducibility of Results | 6 | 2010 | 3083 | 0.090 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 380 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2010 | 131 | 0.080 |
Why?
|
| Estrenes | 1 | 2010 | 16 | 0.080 |
Why?
|
| DNA Damage | 2 | 2024 | 384 | 0.080 |
Why?
|
| Nucleic Acid Denaturation | 1 | 2009 | 32 | 0.080 |
Why?
|
| DNA Primers | 2 | 2009 | 510 | 0.080 |
Why?
|
| Tissue Fixation | 1 | 2009 | 34 | 0.080 |
Why?
|
| Paraffin Embedding | 1 | 2009 | 29 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 180 | 0.080 |
Why?
|
| Homozygote | 1 | 2010 | 193 | 0.080 |
Why?
|
| Oncogene Protein pp60(v-src) | 1 | 2009 | 5 | 0.080 |
Why?
|
| Formaldehyde | 1 | 2009 | 60 | 0.080 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2009 | 12 | 0.080 |
Why?
|
| Caveolin 1 | 1 | 2009 | 19 | 0.080 |
Why?
|
| Oximes | 2 | 2022 | 22 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2015 | 3240 | 0.080 |
Why?
|
| Cell Separation | 1 | 2010 | 316 | 0.080 |
Why?
|
| Watchful Waiting | 2 | 2019 | 67 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 1367 | 0.080 |
Why?
|
| Aminoquinolines | 1 | 2008 | 21 | 0.080 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 168 | 0.070 |
Why?
|
| Dioxoles | 1 | 2008 | 9 | 0.070 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2008 | 8 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 129 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 336 | 0.070 |
Why?
|
| Dioxolanes | 1 | 2008 | 6 | 0.070 |
Why?
|
| Cytosine | 1 | 2008 | 46 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2008 | 61 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 350 | 0.070 |
Why?
|
| Appointments and Schedules | 1 | 2008 | 84 | 0.070 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 211 | 0.070 |
Why?
|
| Colony-Stimulating Factors | 1 | 2007 | 35 | 0.070 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2008 | 90 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 958 | 0.070 |
Why?
|
| Protein Kinases | 1 | 2009 | 318 | 0.070 |
Why?
|
| HT29 Cells | 2 | 2018 | 36 | 0.070 |
Why?
|
| Pyrroles | 2 | 2022 | 202 | 0.070 |
Why?
|
| Pharmacogenetics | 1 | 2008 | 175 | 0.070 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2008 | 132 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2006 | 80 | 0.070 |
Why?
|
| Benzenesulfonates | 1 | 2006 | 19 | 0.070 |
Why?
|
| Antimitotic Agents | 1 | 2006 | 8 | 0.070 |
Why?
|
| Midazolam | 1 | 2006 | 53 | 0.070 |
Why?
|
| Blood Cells | 1 | 2006 | 39 | 0.070 |
Why?
|
| Estradiol | 1 | 2010 | 494 | 0.070 |
Why?
|
| Cyclooxygenase 2 | 2 | 2006 | 177 | 0.060 |
Why?
|
| Gene Expression | 4 | 2019 | 1472 | 0.060 |
Why?
|
| Bortezomib | 1 | 2006 | 45 | 0.060 |
Why?
|
| Proteasome Inhibitors | 1 | 2006 | 42 | 0.060 |
Why?
|
| Boronic Acids | 1 | 2006 | 37 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2010 | 526 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 173 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 569 | 0.060 |
Why?
|
| Microsomes, Liver | 1 | 2005 | 87 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2017 | 2483 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2012 | 678 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2006 | 148 | 0.060 |
Why?
|
| Phosphorylation | 3 | 2018 | 1713 | 0.060 |
Why?
|
| Spheroids, Cellular | 2 | 2016 | 77 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2005 | 133 | 0.060 |
Why?
|
| Genotype | 1 | 2010 | 1839 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 825 | 0.060 |
Why?
|
| Anemia | 1 | 2006 | 160 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 1198 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2006 | 242 | 0.060 |
Why?
|
| Microsatellite Repeats | 1 | 2024 | 164 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2020 | 1418 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 833 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 73 | 0.050 |
Why?
|
| Age Factors | 2 | 2021 | 3144 | 0.050 |
Why?
|
| Dogs | 3 | 2010 | 381 | 0.050 |
Why?
|
| Age of Onset | 1 | 2024 | 496 | 0.050 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 66 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 171 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 2073 | 0.050 |
Why?
|
| Acetonitriles | 1 | 2022 | 11 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2003 | 302 | 0.050 |
Why?
|
| G2 Phase | 2 | 2014 | 36 | 0.050 |
Why?
|
| Cisplatin | 1 | 2024 | 300 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 1016 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2022 | 67 | 0.050 |
Why?
|
| Calibration | 3 | 2006 | 140 | 0.050 |
Why?
|
| Cancer Vaccines | 1 | 2003 | 164 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2004 | 1288 | 0.050 |
Why?
|
| Reference Standards | 3 | 2006 | 177 | 0.050 |
Why?
|
| Oncogenes | 1 | 2022 | 113 | 0.050 |
Why?
|
| Medical Audit | 1 | 2001 | 77 | 0.050 |
Why?
|
| Cell Division | 2 | 2016 | 797 | 0.050 |
Why?
|
| Chimerism | 1 | 2021 | 31 | 0.050 |
Why?
|
| Algorithms | 2 | 2024 | 1622 | 0.050 |
Why?
|
| Hospitals, University | 1 | 2001 | 179 | 0.050 |
Why?
|
| Lymphoid Tissue | 1 | 2021 | 67 | 0.040 |
Why?
|
| Medical Records | 1 | 2001 | 171 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 2021 | 84 | 0.040 |
Why?
|
| Biomarkers | 3 | 2019 | 3973 | 0.040 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2021 | 20 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2021 | 351 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2022 | 213 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 5440 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 2020 | 88 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 62 | 0.040 |
Why?
|
| Transcriptome | 2 | 2016 | 887 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 33 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2019 | 206 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 119 | 0.040 |
Why?
|
| Small Molecule Libraries | 1 | 2020 | 86 | 0.040 |
Why?
|
| Wnt Proteins | 1 | 2020 | 127 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2019 | 20 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 2005 | 1085 | 0.040 |
Why?
|
| Smad4 Protein | 1 | 2019 | 38 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 588 | 0.040 |
Why?
|
| Survivorship | 1 | 2019 | 48 | 0.040 |
Why?
|
| Risk Factors | 4 | 2019 | 9763 | 0.040 |
Why?
|
| Research Personnel | 1 | 2020 | 156 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 138 | 0.040 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2018 | 24 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 1040 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 548 | 0.040 |
Why?
|
| Colostomy | 1 | 2018 | 26 | 0.040 |
Why?
|
| Adolescent | 3 | 2024 | 20391 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2009 | 1952 | 0.040 |
Why?
|
| 4-Aminobenzoic Acid | 1 | 2018 | 7 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2019 | 188 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 70 | 0.040 |
Why?
|
| Rats | 3 | 2010 | 5499 | 0.040 |
Why?
|
| Calcium | 2 | 2013 | 1213 | 0.040 |
Why?
|
| Anal Canal | 1 | 2018 | 88 | 0.040 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2017 | 14 | 0.040 |
Why?
|
| Palliative Care | 1 | 2024 | 725 | 0.040 |
Why?
|
| Glucuronosyltransferase | 1 | 2017 | 13 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 17 | 0.030 |
Why?
|
| RNA | 1 | 2024 | 883 | 0.030 |
Why?
|
| Education | 1 | 2017 | 101 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 480 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 70 | 0.030 |
Why?
|
| Rectum | 1 | 2018 | 170 | 0.030 |
Why?
|
| Protein Transport | 1 | 2018 | 428 | 0.030 |
Why?
|
| fas Receptor | 1 | 1997 | 95 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 1304 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 1245 | 0.030 |
Why?
|
| Esophagogastric Junction | 1 | 2017 | 50 | 0.030 |
Why?
|
| Retinal Dehydrogenase | 1 | 2016 | 30 | 0.030 |
Why?
|
| Leadership | 1 | 2020 | 354 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 86 | 0.030 |
Why?
|
| Axin Protein | 1 | 2016 | 19 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2017 | 129 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2016 | 96 | 0.030 |
Why?
|
| Cell Movement | 1 | 2021 | 945 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2016 | 42 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 57 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 117 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2016 | 114 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 132 | 0.030 |
Why?
|
| Flavin Mononucleotide | 1 | 1995 | 7 | 0.030 |
Why?
|
| Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 1995 | 4 | 0.030 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 1995 | 8 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 265 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 573 | 0.030 |
Why?
|
| Polymyositis | 1 | 1995 | 15 | 0.030 |
Why?
|
| Flavin-Adenine Dinucleotide | 1 | 1995 | 14 | 0.030 |
Why?
|
| NADP | 1 | 1995 | 46 | 0.030 |
Why?
|
| Ligands | 1 | 2017 | 622 | 0.030 |
Why?
|
| Dermatomyositis | 1 | 1995 | 26 | 0.030 |
Why?
|
| Calmodulin | 1 | 1995 | 76 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1434 | 0.030 |
Why?
|
| History, Ancient | 1 | 2015 | 52 | 0.030 |
Why?
|
| Diphenylamine | 1 | 2014 | 9 | 0.030 |
Why?
|
| Cadherins | 1 | 2016 | 188 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1995 | 100 | 0.030 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2014 | 23 | 0.030 |
Why?
|
| Citrulline | 1 | 1995 | 44 | 0.030 |
Why?
|
| Myositis | 1 | 1995 | 51 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 15 | 0.030 |
Why?
|
| Acid Phosphatase | 1 | 2014 | 20 | 0.030 |
Why?
|
| Rhodamines | 1 | 2014 | 18 | 0.030 |
Why?
|
| Oxaloacetates | 1 | 2014 | 3 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2014 | 55 | 0.030 |
Why?
|
| Ileum | 1 | 1995 | 116 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 287 | 0.030 |
Why?
|
| Histones | 2 | 2010 | 588 | 0.030 |
Why?
|
| Genomics | 1 | 2019 | 716 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1201 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2021 | 2871 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 429 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 1995 | 441 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2014 | 85 | 0.030 |
Why?
|
| Tretinoin | 1 | 2015 | 130 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2016 | 489 | 0.030 |
Why?
|
| Arginine | 1 | 1995 | 265 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1502 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 911 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2001 | 2742 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 1997 | 426 | 0.030 |
Why?
|
| Receptor, Notch2 | 1 | 2013 | 15 | 0.030 |
Why?
|
| Neutrophils | 1 | 2019 | 1205 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2018 | 605 | 0.030 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2013 | 65 | 0.030 |
Why?
|
| Alphapapillomavirus | 1 | 2013 | 40 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 857 | 0.030 |
Why?
|
| Receptors, CXCR | 1 | 2012 | 3 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 840 | 0.030 |
Why?
|
| Phenotype | 1 | 2021 | 3076 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2012 | 63 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2016 | 850 | 0.020 |
Why?
|
| Bile Duct Neoplasms | 1 | 2013 | 99 | 0.020 |
Why?
|
| Logistic Models | 1 | 2017 | 1988 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2014 | 388 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 516 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2017 | 1269 | 0.020 |
Why?
|
| Nausea | 1 | 2012 | 110 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 442 | 0.020 |
Why?
|
| Lymphopenia | 1 | 2012 | 59 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 88 | 0.020 |
Why?
|
| Antioxidants | 1 | 1995 | 559 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 2644 | 0.020 |
Why?
|
| Multiple Sclerosis | 1 | 1997 | 436 | 0.020 |
Why?
|
| Vomiting | 1 | 2012 | 128 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 132 | 0.020 |
Why?
|
| Diarrhea | 1 | 2012 | 180 | 0.020 |
Why?
|
| Models, Biological | 1 | 2018 | 1721 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2013 | 250 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2010 | 29 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2016 | 607 | 0.020 |
Why?
|
| Thalidomide | 1 | 2010 | 32 | 0.020 |
Why?
|
| Lung | 1 | 2023 | 3931 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2012 | 186 | 0.020 |
Why?
|
| Paxillin | 1 | 2009 | 10 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 1587 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 1492 | 0.020 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2009 | 32 | 0.020 |
Why?
|
| Infliximab | 1 | 2009 | 100 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2010 | 242 | 0.020 |
Why?
|
| Indoles | 1 | 2012 | 387 | 0.020 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2009 | 49 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 1997 | 1928 | 0.020 |
Why?
|
| Computational Biology | 1 | 2013 | 599 | 0.020 |
Why?
|
| Species Specificity | 1 | 2010 | 575 | 0.020 |
Why?
|
| Xenopus laevis | 1 | 2008 | 99 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2009 | 338 | 0.020 |
Why?
|
| Staurosporine | 1 | 2007 | 20 | 0.020 |
Why?
|
| Acetylation | 1 | 2008 | 246 | 0.020 |
Why?
|
| Membrane Transport Proteins | 1 | 2008 | 149 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 306 | 0.020 |
Why?
|
| Cyclooxygenase 1 | 1 | 2006 | 26 | 0.020 |
Why?
|
| Celecoxib | 1 | 2006 | 39 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2008 | 503 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2006 | 53 | 0.020 |
Why?
|
| Leukocytes | 1 | 2008 | 304 | 0.020 |
Why?
|
| Clinical Chemistry Tests | 1 | 2006 | 11 | 0.020 |
Why?
|
| Hepatic Artery | 1 | 2006 | 59 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2006 | 111 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 147 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2006 | 186 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2006 | 51 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 545 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 720 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 232 | 0.020 |
Why?
|
| HIV Protease Inhibitors | 1 | 2005 | 68 | 0.020 |
Why?
|
| Ritonavir | 1 | 2005 | 73 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2005 | 368 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2006 | 482 | 0.010 |
Why?
|
| Tubulin | 1 | 2005 | 137 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 2716 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2008 | 867 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 582 | 0.010 |
Why?
|
| Contrast Media | 1 | 2006 | 393 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2008 | 937 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 1642 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 2781 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 716 | 0.010 |
Why?
|
| Hypertension | 1 | 2010 | 1242 | 0.010 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1997 | 21 | 0.010 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1997 | 26 | 0.010 |
Why?
|
| Myelin Basic Protein | 1 | 1997 | 45 | 0.010 |
Why?
|
| Clone Cells | 1 | 1997 | 261 | 0.010 |
Why?
|
| Cell Death | 1 | 1997 | 354 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1997 | 336 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1995 | 332 | 0.010 |
Why?
|
| Multigene Family | 1 | 1995 | 199 | 0.010 |
Why?
|
| Autoantigens | 1 | 1997 | 417 | 0.010 |
Why?
|
| Base Sequence | 1 | 1995 | 2142 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 2058 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 2832 | 0.010 |
Why?
|